Search

Research

In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.

Research

Receiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.

Research

Staphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.

Research

Staphylococcus aureus bacteraemia (SAB) is the most common cause of sepsis, contributing to paediatric intensive care unit admission in Australia and New Zealand. While deep venous thrombosis (DVT) has been reported in children with invasive S. aureus infections, the actual frequency and possible effects of thrombosis on disease severity and outcome in paediatric SAB remain unknown. Moreover, guidance regarding imaging for paediatric SAB management are poorly defined. 

Through co-design with community members, we hope to better understand the strengths and effectiveness of community-driven health promotion resources.

MenABCWY QUINTET Study Meningococcal disease is a rare but serious disease that can result in death if not recognised and treated quickly. There are

News & Events

Vital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at The Kids Research Institute Australia thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant.

PICOBOO (The Platform Trial In COVID-19 Priming and BOOsting) Study and NOVAVAX COVID-19/Influenza Combined Vaccine Study

Research

Small volume assays are required for large-scale research studies and in particular paediatric trials, where multiple measures are required from a single sample. Fluorescent bead-based technology (Bioplex/Luminex) allows high through-put and simultaneous quantification of multiple analytes in a single test. This technology uses sets of microspheres, each with a unique spectral address that can be coated with a different antigen of interest.

News & Events

Children at risk of potentially life-threatening Strep A infections no longer have to wait five days for timely treatment, thanks to a The Kids Research Institute Australia study conducted in the remote Kimberley region of Western Australia.